Clinical intervention over the past two decades has changed HIV infection from a death sentence to a chronic disease. Despite pharmacological management of HIV-infection, approximately 50% of patients continue to present with neurologic impairment termed HIV-associated neurocognitive disorders (HAND), with persistent neuroinflammation and oxidative tissue damage. Current approaches to mitigate HAND have focused on agents targeting a single cellular function, which may limit their efficacy in a complex multisystem disease. Therefore, novel, pluripotent agents capable of acting simultaneously on diverse pathways and cellular processes may present an opportunity in the short and long term management of HIV. Thus, brain penetrant agents capable of controlling oxidative and inflammatory processes with minimal toxicity over prolonged administration to humans are attractive candidates in mitigating or preventing such effects associated with HAND. Our group has been investigating protective properties of secoisolariciresinol diglucoside (SDG), the main bioactive lignan phenolic in wholegrain flaxseed. Dietary SDG boosts endogenous antioxidant defenses in murine tissues, and exhibits potent anti-inflammatory and antioxidant activity in several tissues including the CNS. SDG and its metabolites can cross the blood-brain barrier (BBB) and enter brain tissues, making it an attractive candidate for mitigation of HIV-induced neurotoxicity. We therefore hypothesize that SDG, as a pluripotent agent, will mitigate HIV-associated neurotoxicity by reducing BBB damage, neuroinflammation, and oxidative stress. SDG is safe and well tolerated in humans and findings from numerous recent clinical trials enhance the translational aspect of our proposed study, which aims to provide novel insights into the usefulness of SDG, and to elucidate its mechanisms of action. Using in vitro modeling, Aims 1-3 will determine the effects of SDG on BBB damage, leukocyte trafficking across the BBB, microglial activation and neurotoxicity induced by HIV infection, and will elucidate mechanisms that underlie the efficacy of SDG as an agent that reduces neuroinflammation and oxidative stress.
Aim 4 will investigate the ability of SDG to mitigate BBB damage, neuroinflammation, oxidative stress and neurotoxicity in the humanized mouse model of HIV infection, the huNSG-HIV mouse. Together, these studies will provide evidence to support SDG as adjunctive treatment for management of HAND.

Public Health Relevance

Despite effective viral control in the periphery and in the cerebral spinal fluid, HIV-infected patients continue to develop HAND in 30-50% of cases. This proposal aims to investigate a compound derived from a natural lignan of flaxseed, secoisolariciresinol diglucoside(SDG) as an adjunctive compound to the current antiretroviral arsenal leading to reduced neuroinflammation, and oxidative damage, and subsequently reducing the cognitive decline, which has been linked to HAND progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH106967-02
Application #
9099956
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Colosi, Deborah
Project Start
2015-07-01
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Dentistry/Oral Hygn
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Erickson, Michelle A; Jude, Joseph; Zhao, Hengjiang et al. (2018) Erratum. FASEB J 32:535
Rom, Slava; Zuluaga-Ramirez, Viviana; Gajghate, Sachin et al. (2018) Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. Mol Neurobiol :
Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L et al. (2018) Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation 15:25
Stern, Anna L; Lee, Rebecca N; Panvelker, Nina et al. (2018) Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response. J Neuroimmune Pharmacol 13:64-76
Seliga, Alecia; Lee, Michael Hweemoon; Fernandes, Nicole C et al. (2018) Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation. Front Immunol 9:156
Stern, Anna L; Ghura, Shivesh; Gannon, Patrick J et al. (2018) BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism. J Neurosci 38:4288-4300
Jackson, Dan P; Ting, Jenhao H; Pozniak, Paul D et al. (2018) Identification and characterization of two novel alternatively spliced E2F1 transcripts in the rat CNS. Mol Cell Neurosci 92:1-11
Erickson, Michelle A; Jude, Joseph; Zhao, Hengjiang et al. (2017) Serum amyloid A: an ozone-induced circulating factor with potentially important functions in the lung-brain axis. FASEB J 31:3950-3965
Gannon, Patrick J; Akay-Espinoza, Cagla; Yee, Alan C et al. (2017) HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via ?-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 187:91-109
Monnerie, Hubert; Romer, Micah; Jensen, Brigid K et al. (2017) Reduced sterol regulatory element-binding protein (SREBP) processing through site-1 protease (S1P) inhibition alters oligodendrocyte differentiation in vitro. J Neurochem 140:53-67

Showing the most recent 10 out of 13 publications